Holen Sie sich die Stockscreener-App
5.005
0.10%
0.005
Schlusskurs vom Vortag:
$5.00
Offen:
$5.01
24-Stunden-Volumen:
88,975
Relative Volume:
0.33
Marktkapitalisierung:
$236.41M
Einnahmen:
$31.37M
Nettoeinkommen (Verlust:
$-53.77M
KGV:
-3.4429
EPS:
-1.4537
Netto-Cashflow:
$-49.02M
1W Leistung:
+12.47%
1M Leistung:
-11.73%
6M Leistung:
-6.45%
1J Leistung:
+4.49%
1-Tages-Spanne:
$4.867
$5.56
1-Wochen-Bereich:
$4.375
$5.56
52-Wochen-Spanne:
$1.97
$7.775
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Firmenname
Silence Therapeutics Plc Adr
Sektor
Branche
Telefon
44-0-20-3457 6900
Adresse
12 HAMMERSMITH GROVE, LONDON
Compare SLN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
5.005 | 236.17M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.75 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.49 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.73 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.78 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.95 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Goldman | Sell |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Aktie (SLN) Neueste Nachrichten
Analysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Price Target at $32.60 - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Shares Down 5.1%Here's What Happened - MarketBeat
Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation - Sahm
H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75 By Investing.com - Investing.com India
H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75 - Investing.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7%Should You Sell? - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7% – Should You Sell? - Defense World
Silence Therapeutics Insider Ups Holding During Year - Sahm
Comparing PMV Pharmaceuticals (NASDAQ:PMVP) & Silence Therapeutics (NASDAQ:SLN) - Defense World
Was Autonomix Medical Inc (AMIX)’s session last reading good? - uspostnews.com
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of “Hold” from Analysts - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Silence Therapeutics appoints CFO Rhonda Hellums to board of directors By Investing.com - Investing.com South Africa
Silence Therapeutics appoints CFO Rhonda Hellums to board of directors - Investing.com
Silence Therapeutics CEO Craig Tooman steps down By Investing.com - Investing.com India
Silence Therapeutics CEO Craig Tooman steps down - Investing.com
Frazier Life Sciences Management L.P. Decreases Holdings in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Does Silence Therapeutics Plc ADR (SLN) offer a good opportunity for investors? - setenews.com
Saturn V Capital Management LP Lowers Position in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Silence Therapeutics Plc ADR (SLN) is looking forward to a strong quarter - Setenews
Falcon’s Beyond Global Inc (FBYD) expanding its growth trajectory ahead - setenews.com
Net current asset value per share of Silence Therapeutics PLC Sponsored ADR – FWB:XRP2 - TradingView
HC Wainwright Has Bullish Forecast for SLN FY2025 Earnings - Defense World
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Barchart.com
Brokerages Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) PT at $32.60 - Defense World
SLN: Revenue fell, net loss widened, and cash will fund operations into 2028, but more funding needed - TradingView
Silence Therapeutics (SLN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Silence Therapeutics (NASDAQ:SLN) Stock Price Down 2.1%Time to Sell? - MarketBeat
Our approach to nucleotide-based therapeutics - AstraZeneca
5 Under-the-Radar Biotech Stocks That Could Soar in 2026 - Barchart.com
Silence Therapeutics completes enrollment in PV treatment study - Investing.com
Check Out Insider Trades For Silence Therapeutics Plc ADR (SLN) Stock - fostersleader.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Average Price Target from Analysts - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
GAMMA Investing LLC Buys 4,773 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Goldman Sachs Group Inc. Sells 12,510 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Consensus Target Price from Analysts - Defense World
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire Inc.
Silence Therapeutics (OTCMKTS:SLNCF) Shares Down 5% – Here’s What Happened - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Silence Therapeutics director Michael Davidson resigns from board By Investing.com - Investing.com South Africa
Silence Therapeutics director Michael Davidson resigns from board - Investing.com
Silence Therapeutics (SLN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus - Nasdaq
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - Yahoo Finance
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - Nasdaq
Finanzdaten der Silence Therapeutics Plc Adr-Aktie (SLN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.88%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):